$514 Million is the total value of Octagon Capital Advisors LP's 28 reported holdings in Q4 2021. The portfolio turnover from Q3 2021 to Q4 2021 was 46.7% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| APLS | Buy | APELLIS PHARMACEUTICALS INC | $95,549,000 | +81.6% | 2,020,911 | +26.6% | 18.59% | +43.6% |
| RCUS | Buy | ARCUS BIOSCIENCES INC | $84,794,000 | +150.6% | 2,095,231 | +116.0% | 16.50% | +98.1% |
| IMAB | Buy | I MABsponsored ads | $49,745,000 | -10.2% | 1,049,691 | +37.3% | 9.68% | -29.0% |
| FDMT | Buy | 4D MOLECULAR THERAPEUTICS IN | $34,030,000 | +51.8% | 1,551,070 | +86.6% | 6.62% | +20.0% |
| BBIO | Buy | BRIDGEBIO PHARMA INC | $29,482,000 | +10.5% | 1,767,486 | +210.4% | 5.74% | -12.7% |
| CLDX | CELLDEX THERAPEUTICS INC NEW | $29,420,000 | -28.4% | 761,398 | 0.0% | 5.72% | -43.4% | |
| ITOS | New | ITEOS THERAPEUTICS INC | $20,988,000 | – | 450,776 | +100.0% | 4.08% | – |
| KROS | New | KEROS THERAPEUTICS INC | $19,906,000 | – | 340,214 | +100.0% | 3.87% | – |
| STOK | Buy | STOKE THERAPEUTICS INC | $18,803,000 | +149.0% | 783,769 | +164.1% | 3.66% | +96.8% |
| VERA | Sell | VERA THERAPEUTICS INCcl a | $17,928,000 | +48.4% | 670,940 | -3.6% | 3.49% | +17.3% |
| GOSS | GOSSAMER BIO INC | $17,114,000 | -10.0% | 1,513,138 | 0.0% | 3.33% | -28.9% | |
| ARVN | Buy | ARVINAS INC | $14,662,000 | +5.9% | 178,500 | +5.9% | 2.85% | -16.3% |
| IPSC | Buy | CENTURY THERAPEUTICS INC | $11,144,000 | -26.5% | 702,623 | +16.6% | 2.17% | -41.9% |
| RNA | AVIDITY BIOSCIENCES INC | $10,617,000 | -3.5% | 446,641 | 0.0% | 2.07% | -23.7% | |
| KDNY | New | CHINOOK THERAPEUTICS INC | $8,155,000 | – | 500,000 | +100.0% | 1.59% | – |
| RXDX | PROMETHEUS BIOSCIENCES INC | $7,908,000 | +66.8% | 200,000 | 0.0% | 1.54% | +31.8% | |
| DYN | DYNE THERAPEUTICS INC | $6,940,000 | -26.8% | 583,649 | 0.0% | 1.35% | -42.1% | |
| Sell | CYTEK BIOSCIENCES INC | $6,528,000 | -39.0% | 400,000 | -20.0% | 1.27% | -51.8% | |
| CRDF | CARDIFF ONCOLOGY INC | $5,906,000 | -9.8% | 982,753 | 0.0% | 1.15% | -28.7% | |
| IMVT | New | IMMUNOVANT INC | $4,881,000 | – | 572,862 | +100.0% | 0.95% | – |
| HLXA | HELIX ACQUISITION CORP | $3,956,000 | +0.2% | 400,000 | 0.0% | 0.77% | -20.8% | |
| GLUE | MONTE ROSA THERAPEUTICS INC | $3,063,000 | -8.3% | 150,000 | 0.0% | 0.60% | -27.6% | |
| AMAM | Sell | AMBRX BIOPHARMA INCsponsored ads | $3,042,000 | -35.6% | 336,868 | -3.8% | 0.59% | -49.1% |
| JYAC | JIYA ACQUISITION CORP | $2,931,000 | -0.1% | 300,000 | 0.0% | 0.57% | -21.1% | |
| OLMA | New | OLEMA PHARMACEUTICALS INC | $2,166,000 | – | 231,417 | +100.0% | 0.42% | – |
| Sell | OMEGA THERAPEUTICS INC | $1,999,000 | -71.4% | 176,470 | -52.3% | 0.39% | -77.4% | |
| CNTB | Sell | CONNECT BIOPHARMA HLDGS LTDads | $1,442,000 | -81.5% | 279,921 | -14.2% | 0.28% | -85.4% |
| CMPX | New | COMPASS THERAPEUTICS INC | $761,000 | – | 240,000 | +100.0% | 0.15% | – |
| Exit | TENAX THERAPEUTICS INC | $0 | – | -30,600 | -100.0% | -0.01% | – | |
| DSGN | Exit | DESIGN THERAPEUTICS INC | $0 | – | -14,926 | -100.0% | -0.05% | – |
| EWTX | Exit | EDGEWISE THERAPEUTICS INC | $0 | – | -50,000 | -100.0% | -0.20% | – |
| PMVP | Exit | PMV PHARMACEUTICALS INC | $0 | – | -100,141 | -100.0% | -0.74% | – |
| IKNA | Exit | IKENA ONCOLOGY INC | $0 | – | -275,000 | -100.0% | -0.86% | – |
| NGM | Exit | NGM BIOPHARMACEUTICALS INC | $0 | – | -200,000 | -100.0% | -1.04% | – |
| ISEE | Exit | IVERIC BIO INC | $0 | – | -277,057 | -100.0% | -1.11% | – |
| CRIS | Exit | CURIS INC | $0 | – | -2,294,721 | -100.0% | -4.42% | – |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2022-02-14
Signatures
The EDGAR filing(s) were signed by:
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| APELLIS PHARMACEUTICALS INC | 12 | Q3 2023 | 33.2% |
| ARCUS BIOSCIENCES INC | 12 | Q3 2023 | 18.1% |
| CELLDEX THERAPEUTICS INC NEW | 12 | Q3 2023 | 10.1% |
| GOSSAMER BIO INC | 12 | Q3 2023 | 6.2% |
| 4D MOLECULAR THERAPEUTICS IN | 10 | Q1 2023 | 6.6% |
| BRIDGEBIO PHARMA INC | 10 | Q3 2023 | 6.6% |
| AVIDITY BIOSCIENCES INC | 10 | Q1 2023 | 3.8% |
| VERA THERAPEUTICS INC | 9 | Q2 2023 | 3.5% |
| DYNE THERAPEUTICS INC | 9 | Q3 2023 | 3.5% |
| STOKE THERAPEUTICS INC | 9 | Q2 2023 | 3.7% |
View Octagon Capital Advisors LP's complete holdings history.
Latest filings
| Type | Filed |
|---|---|
| 13F-HR | 2024-02-14 |
| SC 13G/A | 2024-02-06 |
| SC 13G/A | 2024-02-05 |
| SC 13G | 2024-02-05 |
| 13F-HR | 2023-11-14 |
| 13F-HR | 2023-08-14 |
| 13F-HR | 2023-05-15 |
| 13F-HR | 2023-02-14 |
| SC 13G | 2023-01-25 |
| 13F-HR | 2022-11-14 |
View Octagon Capital Advisors LP's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.